adults in their transition from foster care to independent living in the areas of education, employment and earnings, housing and economic well-being, social support, well-being, health and safety, and criminal involvement. It focuses on helping young adults identify and achieve their goals while developing the skills necessary for independent living.

The evaluation is part of a larger project to help ACF build the evidence base in child welfare through rigorous evaluation of programs, practices, and policies. The activities and products from this project will contribute to evidence building in child welfare and help to determine the effectiveness of a program for youth formerly in foster care on young adult outcomes.

The implementation study will collect information through video conferences and site visits to the participating program and child welfare agency. Data collection activities for the implementation study began, as previously approved by OMB. Additional protocols are proposed as part of the implementation study. Proposed information collection activities include interviews and focus groups with administrators and staff from the program developer, child welfare agency, and program providers; online survey of program staff; interviews with youth who participated in the program; and focus groups with youth who participated in the program and who received services as usual.

Respondents: Program participants, young adults receiving services as usual, agency and program administrators and staff, other program stakeholders.

ANNUAL BURDEN ESTIMATES

Instrument	Respondents	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Average burden per response (in hours)	Total burden (in hours)	Annual burden (in hours)
Burden for previously approved, ongoing data collection						
Site Visit 2 Focus Group Guide for Staff.	LifeSet Specialists	12	1	1.5	18	9
LifeSet Team Supervisors						
Baseline Youth Survey	Youth Formerly in Foster Care.	470	1	0.6	282	141
Administrative data file	Agency and Program Staff	12	1	5	60	30
Burden for newly requested information collection						
Site Visit 3 Interview Guide for Administrators.	Child Welfare Agency Administrators. Licensed LifeSet Experts Provider Agency Administrators LifeSet Developer Administrators Provider Agency Administrators	22	1	1	22	11
Site Visit 3 Focus Group Guide for Staff.	LifeSet Specialists ..... LifeSet Team Supervisors Child Welfare Agency Caseworkers	28	1	1.5	42	21
LifeSet Specialist Survey	LifeSet Specialists	16	1	.3	5	3
Interview Guide for Youth ...	LifeSet Program Youth	12	1	1	12	6
Focus Group Guide for Youth.	LifeSet Program Youth ..... Services As Usual Youth	64	1	1.5	96	48

Estimated Total Annual Burden Hours: 269.

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: 42 U.S.C. 677.

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2022–16791 Filed 8–4–22; 8:45 am]

BILLING CODE 4184–25–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Janina Jiang, M.D., Ph.D. (Respondent), former Assistant Researcher in the Department of Pathology & Laboratory Medicine at the David Geffen School of

Medicine, University of California, Los Angeles (UCLA). Respondent engaged in research misconduct in research included in grant applications submitted for U.S. Public Health Service (PHS) funds, specifically R43 CA228629–01 submitted to the National Cancer Institute (NCI), National Institutes of Health (NIH), UL1 TR000124 submitted to the National Center for Advancing Translational Sciences (NCATS), NIH, and P01 AI131294–01, R01 AI126914–01, R21 AI131013–01, R21 AI131451–01, R21 AI131451–01A1, R21 AI142068–01, R43 AI136224–01, R44 AI126960–01, and R44 AI128983–01 submitted to the National Institute of Allergy and Infectious Diseases (NIAID), NIH. The administrative actions, including supervision for a period of three (3) years, were implemented beginning on July 22, 2022, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Janina Jiang, M.D., Ph.D., University of California, Los Angeles: Based on the report of an investigation conducted by UCLA and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Janina Jiang, former Assistant Researcher in the Department of Pathology & Laboratory Medicine at the David Geffen School of Medicine, UCLA, engaged in research misconduct in research included in grant applications submitted for PHS funds, specifically R43 CA228629–01 submitted to NCI, NIH, UL1 TR000124 submitted to NCATS, NIH, and P01 AI131294–01, R01 AI126914–01, R21 AI131013–01, R21 AI131451–01, R21 AI131451–01A1, R21 AI142068–01, R43 AI136224–01, R44 AI126960–01, and R44 AI128983–01 submitted to NIAID, NIH.

ORI found that Respondent engaged in research misconduct by knowingly and recklessly falsifying and/or fabricating flow cytometry data that were included in the following eleven (11) grant applications submitted for PHS funds:

- R43 CA228629–01, ''CTL Based Therapeutic Vaccine to Prevent or Interrupt HPV Mediated Oncogenesis,'' submitted to NCI, NIH, Awarded Project Dates: September 18, 2018-February 29, 2020.
- UL1 TR000124, ''UCLA Clinical and Translational Science Institute,'' submitted to NCATS, NIH, Awarded Project Dates: June 1, 2011-August 31, 2016.
- P01 AI131294–01, ''Defining Factors Controlling HIV Rebound,'' submitted to NIAID, NIH, Awarded Project Dates: August 10, 2017-July 31, 2022.
- R01 AI126914–01, ''A Recombinant Human Vault CTL-Based HIV Vaccine Component,'' submitted to NIAID, NIH, on December 23, 2015.
- R21 AI131013–01, ''A Novel Cellular Immune Zika Vaccine,'' submitted to NIAID, NIH, on June 14, 2016.
- R21 AI131451–01, ''A Novel Therapeutic Vaccine for HPV Oncogenesis,'' submitted to NIAID, NIH, on June 14, 2016.
- R21 AI131451–01A1, ''A Novel Therapeutic Vaccine for HPV Oncogenesis,'' submitted to NIAID, NIH, on June 13, 2017.
- R21 AI142068–01, ''A Novel Therapeutic Vaccine for HPV Oncogenesis,'' submitted to NIAID, NIH, on February 12, 2018.
- R43 AI136224–01, ''Development of A Novel Pan-Serovar Vaccine for Chlamydia,'' submitted to NIAID, NIH, on April 5, 2017.
- R44 AI126960–01, ''Novel Pan-Serovar Vaccine for Chlamydia,'' submitted to NIAID, NIH, on January 4, 2016.
- R44 AI128983–01, ''Design of a Novel CTL Retargeting Therapeutic HIV Vaccine,'' submitted to NIAID, NIH, on April 2, 2016.

ORI found that Respondent knowingly and recklessly falsified and/or fabricated flow cytometry data to represent interferon-γ (IFN-γ) expression in immune cells of mice administered with human recombinant vaults such that the represented data were incompatible with the raw experimental data. Specifically, Respondent falsified and/or fabricated flow cytometry data to represent:

- IFN-γ expression in the immune cells of mice injected subcutaneously or intranasally with human recombinant vaults containing HIV Gag peptides such that the vaccinated arm of the experiment showed antigen-specific T-cell responses in:

—Figure 6 of UL1 TR000124
—Figure 2 of R43 CA228629–01
—Figure 8 of R21 AI131451–01
—Figure 9 of R21 AI131451–01A1
—Figure 9 of R44 AI126960–01
—Figure 3 of R43 AI136224–01
—Figure 9 of R21 AI131013–01
—Figure 7 of R01 AI126914–01
—Figure 7 of R44 AI128983–01
—Figures 8A and 8B of R21 AI142068–01

- increased IFN-γ expression in the immune cells of mice injected with human recombinant vaults containing HPV peptides in Figure 3 of R43 CA228629–01
- dose-dependent increase in IFN-γ expression in the immune cells of mice injected with human recombinant vaults containing HIV Gag peptides in Figure 8 of P01 AI131294–01 and Figure 8C of R21 AI142068–01
- IFN-γ expression in the immune cells of mice administered intranasally with human recombinant vaults containing HPV peptides in Figure 10 of R21 AI131451–01A1 and Figure 10 of R21 AI142068–01
- IFN-γ expression in the immune cells of mice administered orally with human recombinant vaults containing HIV Gag peptides in Figure 11 of R21 AI131451–01A1 and Figure 9 of R21 AI142068–01
- IFN-γ expression in the immune cells of mice immunized subcutaneously with increasing doses of human recombinant vaults containing HIV Gag-1 spanning peptides in Figure 14 of R01 AI126914–01 and Figure 13 of R44 AI128983–01

Dr. Jiang entered into a Voluntary Settlement Agreement (Agreement) and voluntarily agreed to the following:

(1) Respondent will have her research supervised for a period of three (3) years beginning on July 22, 2022 (the ''Supervision Period''). Prior to the submission of an application for PHS support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity in PHS-supported research, Respondent will submit a plan for supervision of Respondent's duties to ORI for approval. The supervision plan must be designed to ensure the integrity of Respondent's research. Respondent will not participate in any PHS-supported research until such a supervision plan is approved by ORI. Respondent will comply with the agreed-upon supervision plan.

(2) The requirements for Respondent's supervision plan are as follows:

i. A committee of two senior faculty members at the institution who are familiar with Respondent's field of research, but not including Respondent's supervisor or collaborators, will provide oversight and guidance for a period of three (3) years from the effective date of this Agreement. The committee will review Respondent's primary data on a quarterly basis and submit a report to ORI at six (6) month intervals setting forth the committee meeting dates and Respondent's compliance with appropriate research standards and

confirming the integrity of Respondent's research.

ii. The committee will conduct an advance review of each application for PHS funds, or report, manuscript, or abstract involving Respondent's research. The review will include a discussion with Respondent of the primary data represented in those documents and will include a certification to ORI that the Respondent's data presented in the proposed application, report, manuscript, or abstract are supported by the research record.

(3) During the Supervision Period, Respondent will ensure that any institution employing her submits, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported and not plagiarized in the application, report, manuscript, or abstract.

(4) If no supervision plan is provided to ORI, Respondent will provide certification to ORI at the conclusion of the Supervision Period that her participation was not proposed on a research project for which an application for PHS support was submitted and that she has not participated in any capacity in PHS-supported research.

(5) During the Supervision Period, Respondent will exclude herself voluntarily from serving in any advisory or consultant capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee.

Dated: August 2, 2022.

Wanda K. Jones,

Acting Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2022–16867 Filed 8–4–22; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2022–0258]

National Maritime Security Advisory Committee; Vacancies

AGENCY: U.S. Coast Guard, Department of Homeland Security.

ACTION: Request for applications.

SUMMARY: The U.S. Coast Guard seeks applications to fill two member vacancies on the National Maritime Security Advisory Committee (Committee). This Committee provides advice and makes recommendations to the Secretary of Homeland Security, via the Commandant of the U.S. Coast Guard, on matters relating to national maritime security, including on enhancing the sharing of information related to cybersecurity risks that may cause a transportation security incident, between relevant Federal agencies and State, local, and tribal governments; relevant public safety and emergency response agencies; relevant law enforcement and security organizations; maritime industry; port owners and operators; and terminal owners and operators.

DATES: Your completed application should reach the U.S. Coast Guard on or before September 6, 2022.

ADDRESSES: Applications should include a cover letter expressing interest in an appointment to the National Maritime Security Advisory Committee and a resume detailing the applicant's relevant experience for the position applied for, with a brief biography. Incomplete applications will not be considered. Applications should be submitted via email with the subject line ''Application for NMSAC'' to *ryan.f.owens@uscg.mil.*

FOR FURTHER INFORMATION CONTACT: Mr. Ryan Owens, Alternate Designated Federal Officer of the National Maritime Security Advisory Committee; telephone: 202–372–1108 or email at *ryan.f.owens@uscg.mil*

SUPPLEMENTARY INFORMATION: The National Maritime Security Advisory Committee is a Federal advisory committee. The Committee was established on December 4, 2018, by § 602 of the *Frank LoBiondo Coast Guard Authorization Act of 2018,* Public Law 115–282, 132 Stat. 4192, and is codified in 46 U.S.C. 70112. The Committee operates under the provisions of the *Federal Advisory Committee Act,* (5 U.S.C. Appendix), and 46 U.S.C. 15109. The National Maritime Security Advisory Committee provides advice, consults with, and makes recommendations to the Secretary of Homeland Security, via the Commandant of the Coast Guard, on matters relating to national maritime security, including on enhancing the sharing of information related to cybersecurity risks that may cause a transportation security incident, between relevant Federal agencies and—

A. State, local, and tribal governments;

B. relevant public safety and emergency response agencies;

C. relevant law enforcement and security organizations;

D. maritime industry;

E. port owners and operators; and

F. terminal owners and operators.

The Committee is required to meet at least once a year in accordance with 46 U.S.C. 15109(a). We expect the Committee will hold meetings at least twice a year, but it may meet more frequently.

All members serve at their own expense and receive no salary or other compensation from the Federal Government. Members may be reimbursed for travel and per diem in accordance with Federal Travel regulations.

Under the provisions in 46 U.S.C. 15109(f)(6), if you are appointed as a member of the Committee, your membership term will expire on December 31 of the third full year after the effective date of your appointment. In this solicitation for Committee members, we will consider applications for two (2) positions:

- Facilities owners and operators.
- State and local governments.

Each member of the Committee must have particular expertise, knowledge, and experience in matters relating to the function of the Committee, which is to advise the Secretary of Homeland Security on the matters described above.

Consistent with 46 U.S.C. 15109(f)(4), Committee members are required to apply for, obtain, and maintain a government national security clearance at the Secret level. The U.S. Coast Guard will sponsor and assist candidates with this process.

In order for the Department, to fully leverage broad-ranging experience and education, the National Maritime Security Advisory Committee must be diverse with regard to professional and technical expertise. The Department is committed to pursuing opportunities, consistent with applicable law, to compose a committee that reflects the diversity of the nation's people.

If you are interested in applying to become a member of the Committee, email your cover letter and resume along with the brief biography to *ryan.f.owens@uscg.mil* via the transmittal method in the **ADDRESSES** section by the deadline in the **DATES** section of this notice.